Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors

BACKGROUND: The clinical value of postoperative adjuvant therapy (PAT) for hepatocellular carcinoma (HCC) remains unclear. This study aimed to explore the effect of PAT with tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies on the surgical outcomes of HCC patients with high-risk recurrent f...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jian, Wang, Wen-qiang, Zhu, Rong-hua, Lv, Xing, Wang, Jin-lin, Liang, Bin-yong, Zhang, Er-lei, Huang, Zhi-yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285103/
https://www.ncbi.nlm.nih.gov/pubmed/37359534
http://dx.doi.org/10.3389/fimmu.2023.1202039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285103/
https://www.ncbi.nlm.nih.gov/pubmed/37359534
http://dx.doi.org/10.3389/fimmu.2023.1202039

Ejemplares similares